CN102356081B - 减少β-淀粉状蛋白生成的双环化合物 - Google Patents
减少β-淀粉状蛋白生成的双环化合物 Download PDFInfo
- Publication number
- CN102356081B CN102356081B CN201080012637.2A CN201080012637A CN102356081B CN 102356081 B CN102356081 B CN 102356081B CN 201080012637 A CN201080012637 A CN 201080012637A CN 102356081 B CN102356081 B CN 102356081B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- azepine
- triazolo
- amine
- tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCC(*)C1*2=*C(C(CCC)**)=**2CCC1 Chemical compound CCCC(*)C1*2=*C(C(CCC)**)=**2CCC1 0.000 description 10
- MAQCLDPJGCDAER-UHFFFAOYSA-N C(CC[n]1nc(Nc(cc2)ccc2-[n]2cncc2)nc11)CC1c1ccccc1 Chemical compound C(CC[n]1nc(Nc(cc2)ccc2-[n]2cncc2)nc11)CC1c1ccccc1 MAQCLDPJGCDAER-UHFFFAOYSA-N 0.000 description 1
- YTNLHGZCYNIAAC-UHFFFAOYSA-N C=C(CCC(C(O)=O)c(cc1)ccc1F)CCl Chemical compound C=C(CCC(C(O)=O)c(cc1)ccc1F)CCl YTNLHGZCYNIAAC-UHFFFAOYSA-N 0.000 description 1
- RJDZXQFELVERHC-UHFFFAOYSA-N C=CC[n]1nc(Nc(cc2)ccc2-[n]2cncc2)nc1C(C=C)c1ccccc1 Chemical compound C=CC[n]1nc(Nc(cc2)ccc2-[n]2cncc2)nc1C(C=C)c1ccccc1 RJDZXQFELVERHC-UHFFFAOYSA-N 0.000 description 1
- IPAMWANOIMPNEY-YWFITGJYSA-N CC(C)=C/C(/F)=C\C([C@H]1c2nc(Nc(cc3)cc(OC)c3-[n]3cnc(Cl)c3)n[n]2CCCC1)=C Chemical compound CC(C)=C/C(/F)=C\C([C@H]1c2nc(Nc(cc3)cc(OC)c3-[n]3cnc(Cl)c3)n[n]2CCCC1)=C IPAMWANOIMPNEY-YWFITGJYSA-N 0.000 description 1
- ZAZXHSMRSZYHCM-UHFFFAOYSA-N CC(N(C=N)c(cc1)ccc1/N=C(/N)\SC)=C Chemical compound CC(N(C=N)c(cc1)ccc1/N=C(/N)\SC)=C ZAZXHSMRSZYHCM-UHFFFAOYSA-N 0.000 description 1
- FBGWCBVRZBDNHB-UHFFFAOYSA-N CC(N(C=N)c(cc1)ccc1Nc1n[n](CC=CCC2c3ccccc3)c2n1)=C Chemical compound CC(N(C=N)c(cc1)ccc1Nc1n[n](CC=CCC2c3ccccc3)c2n1)=C FBGWCBVRZBDNHB-UHFFFAOYSA-N 0.000 description 1
- JOTPJMCNDMLYOB-UHFFFAOYSA-N CC1=CCC=CCC(c2ccccc2)C1=C=C Chemical compound CC1=CCC=CCC(c2ccccc2)C1=C=C JOTPJMCNDMLYOB-UHFFFAOYSA-N 0.000 description 1
- JDASYXQNXJFWFU-UHFFFAOYSA-N CCC(CC[n]1nc(Nc(cc2)cc(OC)c2-[n]2cnc(Cl)c2)nc11)(CC1c(cc1)ccc1[F]CC(C)CI)O Chemical compound CCC(CC[n]1nc(Nc(cc2)cc(OC)c2-[n]2cnc(Cl)c2)nc11)(CC1c(cc1)ccc1[F]CC(C)CI)O JDASYXQNXJFWFU-UHFFFAOYSA-N 0.000 description 1
- DMIMNTZYKXYHBV-UHFFFAOYSA-N COc(cc(cc1)Nc2nc(C(CC(C3)N)c(cc4)ccc4F)c3[s]2)c1-[n]1cnc(Cl)c1 Chemical compound COc(cc(cc1)Nc2nc(C(CC(C3)N)c(cc4)ccc4F)c3[s]2)c1-[n]1cnc(Cl)c1 DMIMNTZYKXYHBV-UHFFFAOYSA-N 0.000 description 1
- HJXBHEIIOYUDBN-UHFFFAOYSA-N COc1c(-[n]2cnc(Cl)c2)ncc(/N=C(/N)\SC)c1 Chemical compound COc1c(-[n]2cnc(Cl)c2)ncc(/N=C(/N)\SC)c1 HJXBHEIIOYUDBN-UHFFFAOYSA-N 0.000 description 1
- PSEFVMGPHXRUBZ-UHFFFAOYSA-N COc1cc(/N=C(/N)\SC)ccc1-[n](cn1)nc1Cl Chemical compound COc1cc(/N=C(/N)\SC)ccc1-[n](cn1)nc1Cl PSEFVMGPHXRUBZ-UHFFFAOYSA-N 0.000 description 1
- HWOBEBGJAOYKNL-SFHVURJKSA-N Cc(nc1)c[n]1-c(ccc(Nc1n[n](CCCC[C@H]2c(cc3F)ccc3F)c2n1)c1)c1OC Chemical compound Cc(nc1)c[n]1-c(ccc(Nc1n[n](CCCC[C@H]2c(cc3F)ccc3F)c2n1)c1)c1OC HWOBEBGJAOYKNL-SFHVURJKSA-N 0.000 description 1
- VLKODRFKRAQJQJ-UHFFFAOYSA-N Cc(nc1)n[n]1-c(c(F)c1)ccc1/N=C(/N)\SC Chemical compound Cc(nc1)n[n]1-c(c(F)c1)ccc1/N=C(/N)\SC VLKODRFKRAQJQJ-UHFFFAOYSA-N 0.000 description 1
- MZOJBYNMNGPCME-GOSISDBHSA-N Cc(nc1)n[n]1-c(c(OC)c1)cc(F)c1Nc1n[n](CCCC[C@@H]2c(cc3)ccc3OCC(F)(F)F)c2n1 Chemical compound Cc(nc1)n[n]1-c(c(OC)c1)cc(F)c1Nc1n[n](CCCC[C@@H]2c(cc3)ccc3OCC(F)(F)F)c2n1 MZOJBYNMNGPCME-GOSISDBHSA-N 0.000 description 1
- MZOJBYNMNGPCME-SFHVURJKSA-N Cc(nc1)n[n]1-c(c(OC)c1)cc(F)c1Nc1n[n](CCCC[C@H]2c(cc3)ccc3OCC(F)(F)F)c2n1 Chemical compound Cc(nc1)n[n]1-c(c(OC)c1)cc(F)c1Nc1n[n](CCCC[C@H]2c(cc3)ccc3OCC(F)(F)F)c2n1 MZOJBYNMNGPCME-SFHVURJKSA-N 0.000 description 1
- WSRLYKGEFMSYDL-UHFFFAOYSA-N Cc(nc1)n[n]1-c(ccc(/N=C(/N)\SC)c1)c1OC Chemical compound Cc(nc1)n[n]1-c(ccc(/N=C(/N)\SC)c1)c1OC WSRLYKGEFMSYDL-UHFFFAOYSA-N 0.000 description 1
- ZGEIPGMPHOCQIY-UHFFFAOYSA-N Cc(nc1)n[n]1-c(ccc(Nc1n[n](CCCCC2c(cc3)ccc3OCC(F)(F)F)c2n1)c1)c1F Chemical compound Cc(nc1)n[n]1-c(ccc(Nc1n[n](CCCCC2c(cc3)ccc3OCC(F)(F)F)c2n1)c1)c1F ZGEIPGMPHOCQIY-UHFFFAOYSA-N 0.000 description 1
- KUZYSMDWIOFTLE-UHFFFAOYSA-N Cc(nc1)n[n]1-c(ccc(Nc1nc(C(CCC2)(c3ccccc3)N)c2[s]1)c1)c1OC Chemical compound Cc(nc1)n[n]1-c(ccc(Nc1nc(C(CCC2)(c3ccccc3)N)c2[s]1)c1)c1OC KUZYSMDWIOFTLE-UHFFFAOYSA-N 0.000 description 1
- KZLXVZPCRITYHZ-LJQANCHMSA-N Cc1cc([C@@H]2c3nc(Nc(cc4)cc(OC)c4-[n]4cnc(Cl)c4)n[n]3CCCC2)cc(F)c1 Chemical compound Cc1cc([C@@H]2c3nc(Nc(cc4)cc(OC)c4-[n]4cnc(Cl)c4)n[n]3CCCC2)cc(F)c1 KZLXVZPCRITYHZ-LJQANCHMSA-N 0.000 description 1
- GOLUZQYFQAIUDQ-UHFFFAOYSA-N Cc1ncn[n]1-c(ccc(Nc1n[n](CCCCC2c(cc3)ccc3F)c2n1)c1)c1F Chemical compound Cc1ncn[n]1-c(ccc(Nc1n[n](CCCCC2c(cc3)ccc3F)c2n1)c1)c1F GOLUZQYFQAIUDQ-UHFFFAOYSA-N 0.000 description 1
- DRNPZCODRJLFSL-SFHVURJKSA-N Cc1ncn[n]1-c(ccc(Nc1n[n](CCCC[C@H]2c(cc3)ccc3OC(F)(F)F)c2n1)c1)c1F Chemical compound Cc1ncn[n]1-c(ccc(Nc1n[n](CCCC[C@H]2c(cc3)ccc3OC(F)(F)F)c2n1)c1)c1F DRNPZCODRJLFSL-SFHVURJKSA-N 0.000 description 1
- FRNKLGBBBIOTDG-ZWKOTPCHSA-N Cc1ncn[n]1-c(ccc(Nc1n[n](CC[C@@H](C[C@@H]2c(cc3)ccc3F)O)c2n1)c1)c1F Chemical compound Cc1ncn[n]1-c(ccc(Nc1n[n](CC[C@@H](C[C@@H]2c(cc3)ccc3F)O)c2n1)c1)c1F FRNKLGBBBIOTDG-ZWKOTPCHSA-N 0.000 description 1
- FRNKLGBBBIOTDG-QZTJIDSGSA-N Cc1ncn[n]1-c(ccc(Nc1n[n](CC[C@H](C[C@@H]2c(cc3)ccc3F)O)c2n1)c1)c1F Chemical compound Cc1ncn[n]1-c(ccc(Nc1n[n](CC[C@H](C[C@@H]2c(cc3)ccc3F)O)c2n1)c1)c1F FRNKLGBBBIOTDG-QZTJIDSGSA-N 0.000 description 1
- PFCNBNJFKHHSSH-UHFFFAOYSA-N O=C(C(CC1(C2)OCCO1)c(cc1)ccc1F)C2Br Chemical compound O=C(C(CC1(C2)OCCO1)c(cc1)ccc1F)C2Br PFCNBNJFKHHSSH-UHFFFAOYSA-N 0.000 description 1
- XXPITDTYKNUMLO-UHFFFAOYSA-N OC(C(CCCCCl)c(cc1)ccc1OCC(F)(F)F)=O Chemical compound OC(C(CCCCCl)c(cc1)ccc1OCC(F)(F)F)=O XXPITDTYKNUMLO-UHFFFAOYSA-N 0.000 description 1
- UFBYPOPPLDNOIT-UHFFFAOYSA-N OC(C(CCCCCl)c(cn1)ccc1Cl)=O Chemical compound OC(C(CCCCCl)c(cn1)ccc1Cl)=O UFBYPOPPLDNOIT-UHFFFAOYSA-N 0.000 description 1
- IFMWVSXGMHQEEA-UHFFFAOYSA-N OC(C(CCCCCl)c1cc(Cl)ccc1)=O Chemical compound OC(C(CCCCCl)c1cc(Cl)ccc1)=O IFMWVSXGMHQEEA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14531909P | 2009-01-16 | 2009-01-16 | |
| US61/145319 | 2009-01-16 | ||
| PCT/US2010/020710 WO2010083141A1 (en) | 2009-01-16 | 2010-01-12 | Bicyclic compounds for the reduction of beta-amyloid production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102356081A CN102356081A (zh) | 2012-02-15 |
| CN102356081B true CN102356081B (zh) | 2014-08-27 |
Family
ID=42061022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080012637.2A Expired - Fee Related CN102356081B (zh) | 2009-01-16 | 2010-01-12 | 减少β-淀粉状蛋白生成的双环化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8349880B2 (https=) |
| EP (1) | EP2379553B1 (https=) |
| JP (1) | JP5638007B2 (https=) |
| CN (1) | CN102356081B (https=) |
| AR (1) | AR075139A1 (https=) |
| ES (1) | ES2426023T3 (https=) |
| TW (1) | TW201030002A (https=) |
| WO (1) | WO2010083141A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2742897A1 (en) | 2008-11-06 | 2010-05-14 | Astrazeneca Ab | Modulators of amyloid beta. |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| WO2010089292A1 (en) | 2009-02-06 | 2010-08-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| AU2010262036B2 (en) | 2009-05-07 | 2014-10-30 | Cellzome Limited | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| JP2012532912A (ja) | 2009-07-15 | 2012-12-20 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体 |
| BR112012017310A2 (pt) * | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | derivados de triazol substituídos como moduladores de gama secretase |
| LT2603513T (lt) | 2010-08-10 | 2020-05-25 | Takeda Pharmaceutical Company Limited | Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus |
| BR112013004746A2 (pt) | 2010-09-02 | 2016-06-07 | Takeda Pharmaceutical | "composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto." |
| TW201309655A (zh) * | 2011-01-28 | 2013-03-01 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
| AU2012230348A1 (en) | 2011-03-24 | 2013-08-29 | Cellzome Limited | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
| EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| KR101913135B1 (ko) | 2011-07-15 | 2018-10-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 |
| US9181245B2 (en) | 2012-05-16 | 2015-11-10 | Janssen Pharmaceuticals, Inc. | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease |
| EP2687528A1 (en) | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
| CA2891755C (en) | 2013-01-17 | 2021-10-26 | Janssen Pharmaceutica Nv | Substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| EP2958918B1 (en) * | 2013-02-21 | 2016-12-07 | Boehringer Ingelheim International GmbH | Dihydropteridinones ii |
| WO2014195323A1 (en) | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Pyrimidine compounds and their use as gamma secretase modulators |
| JP6368776B2 (ja) | 2013-06-04 | 2018-08-01 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| JP6396438B2 (ja) | 2013-06-04 | 2018-09-26 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ.ホフマン-ラ ロシュ アーゲー | γ-セクレターゼモジュレーターとしてのトリアゾロピリジン |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| WO2018083050A1 (en) * | 2016-11-01 | 2018-05-11 | F. Hoffmann-La Roche Ag | Bicyclic heteroaryl derivatives |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2019121434A1 (en) * | 2017-12-18 | 2019-06-27 | F. Hoffmann-La Roche Ag | Triazolo-azepine derivatives |
| CN111417636B (zh) * | 2018-01-22 | 2023-09-26 | 豪夫迈·罗氏有限公司 | 三唑并-氮杂䓬衍生物 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| AU2020348675B2 (en) | 2019-09-16 | 2025-11-20 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2H)-one derivatives |
| EP4065581B1 (en) | 2019-11-29 | 2024-07-24 | F. Hoffmann-La Roche AG | Process for the preparation (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
| WO2024032584A1 (zh) * | 2022-08-08 | 2024-02-15 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其医疗用途 |
| CN120324393B (zh) * | 2025-05-20 | 2025-11-04 | 广东海洋大学 | (2,4-二氯苯基)甲基硫基甲烷脒及其盐的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059955A1 (es) * | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
| AU2008248129B8 (en) * | 2007-05-07 | 2013-05-30 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| EP2155740B1 (en) | 2007-05-11 | 2011-01-26 | F. Hoffmann-La Roche AG | Hetarylanilines as modulators for amyloid beta |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| ES2529648T3 (es) | 2007-08-31 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Compuesto policíclico |
| ES2375919T3 (es) | 2008-01-11 | 2012-03-07 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide. |
| MX2010008700A (es) | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
-
2009
- 2009-12-31 TW TW098146451A patent/TW201030002A/zh unknown
-
2010
- 2010-01-07 US US12/683,791 patent/US8349880B2/en active Active
- 2010-01-12 CN CN201080012637.2A patent/CN102356081B/zh not_active Expired - Fee Related
- 2010-01-12 JP JP2011546297A patent/JP5638007B2/ja not_active Expired - Fee Related
- 2010-01-12 EP EP10700643.9A patent/EP2379553B1/en not_active Not-in-force
- 2010-01-12 WO PCT/US2010/020710 patent/WO2010083141A1/en not_active Ceased
- 2010-01-12 ES ES10700643T patent/ES2426023T3/es active Active
- 2010-01-15 AR ARP100100099A patent/AR075139A1/es not_active Application Discontinuation
Non-Patent Citations (2)
| Title |
|---|
| β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer′s Disease;D.A. Butterfield 等;《Biochemical and Biophysical Research Communications》;19940430;第200卷(第2期);第710-715页 * |
| 人参皂苷Rbl抑制p淀粉样蛋白笛塔诱导的皮层神经元tau蛋白过度磷酸化;曾育琦 等;《药学学报》;20050630;第40卷(第3期);第225-230页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2379553B1 (en) | 2013-06-26 |
| ES2426023T3 (es) | 2013-10-18 |
| EP2379553A1 (en) | 2011-10-26 |
| TW201030002A (en) | 2010-08-16 |
| JP2012515205A (ja) | 2012-07-05 |
| JP5638007B2 (ja) | 2014-12-10 |
| AR075139A1 (es) | 2011-03-09 |
| US8349880B2 (en) | 2013-01-08 |
| WO2010083141A1 (en) | 2010-07-22 |
| US20110015175A1 (en) | 2011-01-20 |
| CN102356081A (zh) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102356081B (zh) | 减少β-淀粉状蛋白生成的双环化合物 | |
| JP7453989B2 (ja) | 抗癌剤として有用な縮合三環式化合物 | |
| JP6712344B2 (ja) | Betタンパク質阻害剤としての三環式複素環 | |
| JP5666304B2 (ja) | 新規な縮合アミノジヒドロチアジン誘導体 | |
| CN102971325B (zh) | 用于减少β-淀粉样蛋白产生的化合物 | |
| US9079914B2 (en) | Fused aminodihydro-oxazine derivatives | |
| CN112770745B (zh) | 用于治疗特定白血病的化合物 | |
| KR101428346B1 (ko) | 벤즈옥사제핀 pi3k 억제 화합물 및 사용 방법 | |
| CN108558871B (zh) | 作为抗癌剂的三环化合物 | |
| JP2019206584A (ja) | BETタンパク質阻害剤としての1H−ピロロ[2,3−c]ピリジン−7(6H)−オン及びピラゾロ[3,4−c]ピリジン−7(6H)−オン | |
| CN114072393A (zh) | 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物 | |
| TW201107311A (en) | Compounds for the reduction of β-amyloid production | |
| CN101815713A (zh) | 多环化合物 | |
| TW201441233A (zh) | 作爲β-分泌酶抑制劑之稠合多環的碸化合物及其使用方法 | |
| HK40129049A (zh) | 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物 | |
| TW202545520A (zh) | 化合物及其醫藥用途 | |
| HK40123924A (zh) | 作为qpctl和qpct抑制剂用於治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1,2,4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物 | |
| CN116640156A (zh) | Ripk1抑制剂 | |
| HK40052099A (en) | Compounds for treating certain leukemias | |
| HK40052099B (en) | Compounds for treating certain leukemias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20170112 |